Rhumbline Advisers Has $4.57 Million Holdings in U.S. Physical Therapy, Inc. (NYSE:USPH)

Rhumbline Advisers lowered its stake in U.S. Physical Therapy, Inc. (NYSE:USPH) by 1.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 51,462 shares of the company’s stock after selling 584 shares during the quarter. Rhumbline Advisers owned 0.34% of U.S. Physical Therapy worth $4,565,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. KBC Group NV increased its stake in U.S. Physical Therapy by 68.6% in the third quarter. KBC Group NV now owns 774 shares of the company’s stock valued at $66,000 after purchasing an additional 315 shares in the last quarter. Pacer Advisors Inc. bought a new stake in U.S. Physical Therapy in the 4th quarter valued at about $113,000. First Horizon Advisors Inc. raised its stake in U.S. Physical Therapy by 25.1% during the 3rd quarter. First Horizon Advisors Inc. now owns 1,486 shares of the company’s stock worth $126,000 after buying an additional 298 shares during the period. International Assets Investment Management LLC boosted its holdings in U.S. Physical Therapy by 8,414.8% in the third quarter. International Assets Investment Management LLC now owns 2,299 shares of the company’s stock worth $195,000 after acquiring an additional 2,272 shares in the last quarter. Finally, Sugar Maple Asset Management LLC acquired a new stake in U.S. Physical Therapy in the third quarter valued at approximately $212,000.

U.S. Physical Therapy Stock Performance

Shares of USPH stock opened at $82.25 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.78 and a quick ratio of 1.78. The firm has a 50-day moving average of $88.41 and a 200-day moving average of $87.67. U.S. Physical Therapy, Inc. has a one year low of $76.18 and a one year high of $113.63. The company has a market cap of $1.24 billion, a P/E ratio of 87.50, a P/E/G ratio of 3.54 and a beta of 1.48.

U.S. Physical Therapy (NYSE:USPH) last posted its quarterly earnings data on Wednesday, February 26th. The company reported $0.65 EPS for the quarter, missing the consensus estimate of $0.69 by ($0.04). U.S. Physical Therapy had a net margin of 3.54% and a return on equity of 8.11%. The firm had revenue of $180.45 million during the quarter, compared to analysts’ expectations of $173.10 million. Equities research analysts forecast that U.S. Physical Therapy, Inc. will post 2.67 EPS for the current fiscal year.

U.S. Physical Therapy Dividend Announcement

The firm also recently announced a dividend, which will be paid on Friday, April 11th. Stockholders of record on Friday, March 14th will be paid a dividend of $0.45 per share. The ex-dividend date of this dividend is Friday, March 14th. U.S. Physical Therapy’s payout ratio is 187.23%.

Insider Buying and Selling

In other U.S. Physical Therapy news, CFO Carey P. Hendrickson sold 516 shares of U.S. Physical Therapy stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $96.25, for a total value of $49,665.00. Following the sale, the chief financial officer now owns 20,469 shares of the company’s stock, valued at approximately $1,970,141.25. The trade was a 2.46 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 1.70% of the stock is owned by insiders.

Analyst Ratings Changes

USPH has been the topic of a number of research reports. JPMorgan Chase & Co. upped their target price on U.S. Physical Therapy from $117.00 to $120.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 3rd. William Blair restated a “market perform” rating on shares of U.S. Physical Therapy in a report on Thursday. Citizens Jmp upgraded shares of U.S. Physical Therapy to a “strong-buy” rating in a report on Monday, December 16th. Bank of America upgraded shares of U.S. Physical Therapy from a “neutral” rating to a “buy” rating and upped their target price for the stock from $100.00 to $115.00 in a report on Monday, December 16th. Finally, JMP Securities started coverage on U.S. Physical Therapy in a research note on Monday, December 16th. They set an “outperform” rating and a $113.00 price target for the company. Two analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $114.00.

U.S. Physical Therapy Company Profile

U.S. Physical Therapy, Inc operates outpatient physical therapy clinics. The company operates through Physical Therapy Operations and Industrial Injury Prevention Services segments. The company provides pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.